Paramount stock rises after FCC approves Skydance merger
PALO ALTO, Calif. - Guardant Health, Inc. (NASDAQ: GH), a $5.6 billion market cap pioneer in precision oncology, has entered into a strategic collaboration with global pharmaceutical giant Pfizer Inc. (NYSE: PFE). The alliance aims to leverage Guardant’s liquid biopsy portfolio for the development and commercialization of Pfizer’s oncology treatments. According to InvestingPro data, Guardant’s stock has shown remarkable strength, delivering a 152% return over the past year.
The multi-year agreement will see the integration of Guardant’s liquid biopsy tests into Pfizer’s worldwide clinical studies. Furthermore, the partnership will evaluate the clinical utility of circulating tumor DNA (ctDNA) levels as a potential surrogate endpoint for monitoring therapy response, along with related blood-based epigenomic analyses. The company’s strong financial position is evident in its healthy current ratio of 4.68, indicating robust liquidity to support its expansion plans.
In addition to supporting Pfizer’s global clinical trials, the collaboration grants Pfizer access to Guardant’s liquid biopsy tests in China, which could be pivotal given the country’s high incidence of cancer-related deaths. This move builds on Guardant’s July 2022 partnership with Adicon Holdings Limited, a prominent clinical laboratory company in China, to provide testing for biopharmaceutical clinical trials.
Guardant Health, founded in 2012, is dedicated to improving patient care and expediting the development of new cancer therapies by offering insights through advanced blood and tissue tests, real-world data, and AI analytics. Their tests span across various stages of cancer care, from early detection to monitoring and treatment selection for advanced cancer. The company has demonstrated strong growth momentum, with revenue increasing by 31% in the last twelve months. For detailed analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 top US stocks.
The press release includes forward-looking statements regarding the potential benefits of the collaboration and Guardant Health’s liquid biopsy tests. However, these statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations. While analysts maintain a strong buy consensus on the stock, InvestingPro analysis indicates the company is currently trading above its Fair Value, with additional ProTips available for subscribers.
The information in this article is based on a press release statement from Guardant Health, Inc.
In other recent news, Guardant Health has announced several significant developments. The company secured a lease extension for its Redwood City facilities through 2031, ensuring stable operational costs and continuity in its core business. In partnership news, Guardant Health has teamed up with Bayshore HealthCare to offer its cancer diagnostic tests in Canada, potentially enhancing access to advanced screening tools for over 350,000 patients annually. Additionally, the U.S. Department of Veterans Affairs has expanded coverage to include Guardant Health’s Shield blood test for colorectal cancer screening, offering it as a no-copay benefit to eligible veterans aged 45 and older. This marks the first time the Shield test is covered for non-Medicare beneficiaries within the 45-64 age group.
Meanwhile, Mizuho Securities initiated coverage on Guardant Health with an Outperform rating and a $55 price target, highlighting the company’s growth potential in the precision oncology market. The analysts note the company’s immediate access to a $20 billion total addressable market and anticipate increased cash flow and profitability from product adoption. The lease extension, partnership, and VA coverage are aligned with Guardant Health’s strategic goals to expand its market presence and improve patient outcomes. These recent developments underscore the company’s efforts to enhance early cancer detection and treatment options.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.